Biomarkers, Clinical Characteristics and Treatment of Bipolar Disorder
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".
Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 1244
Special Issue Editors
Interests: bipolar depression; augmentation strategies; pharmacogenomics; biomarkers
Interests: bipolar disorder; cyclothymia; mood or anxiety disorders
Special Issues, Collections and Topics in MDPI journals
2. Department of Neuroscience, Padova Neuroscience Center, University of Padova, 35127 Padua, Italy
Interests: psychopathology; bipolar disorder; clinical assessment; mental illness; neuropsychopharmacology
Special Issue Information
Dear Colleagues,
This Special Issue will focus on recent advances in the diagnosis and pharmacological treatment of bipolar disorder (BD). BD is a complex and chronic condition with high clinical heterogeneity, frequent psychiatric and general medicine comorbidities, and variable course trajectories. Depression usually represents the prominent mood polarity over the lifespan of people with BD, accounting for its significant morbidity and mortality. Depression may also account for the delayed recognition of BD until a full-threshold (hypo-) manic episode occurs, potentially leading to improper clinical management, increased risk for mixed features of BD, rapid-cycling course, and suicidal behavior, among other outcomes. Pharmacotherapy options both for the acute and maintenance phase of BD have included several medicines, namely, mood stabilizers, antipsychotics, and antidepressants, requiring polypharmacotherapy in most cases to achieve stabilization although there has been concern regarding the overall efficacy as well as the emergence of side effects (eg., metabolic syndrome and antidepressant treatment emergent mania). In recent decades, intense efforts from pre-clinical and clinical perspectives have been dedicated towards developing a better understanding of the neurobiological (i.e., neuro imaging and peripheral and genetic biomarkers) underpinnings of bipolar depression. However, additional insights are warranted, especially compared to acute mania, for which lithium was proposed as an avenue toward understanding the neurobiological bases (though no equivalent agent exists for bipolar depression, to date). Therefore, greater precision on pharmacotherapy recommendations personalizing treatment may potentially improve overall effectiveness. Similarly, psychosocial interventions (psychoeducation, interpersonal, or cognitive behavioral therapy) and neuromodulation techniques can improve overall outcomes.
In this Special Issue, we will welcome case reports, qualitative and quantitative reviews, and clinical studies underscoring diagnostic controversies, clinical correlations with treatment outcomes, risk and protective factors, perspectives, and challenges in new pharmacological treatments as well as psychosocial and neuromodulation interventions that may all provide a better understanding of the pathophysiology and effective ways to personalize treatment in BD.
Dr. Nicolas A. Nunez
Prof. Dr. Michele Fornaro
Dr. Alessandro Miola
Dr. Boney Joseph
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- bipolar disorder
- pharmacological treatment
- biomarkers
